KR20030020488A - Pharmaceutical composition for healing burn-injury comprising bamboo extract as active ingredient - Google Patents

Pharmaceutical composition for healing burn-injury comprising bamboo extract as active ingredient Download PDF

Info

Publication number
KR20030020488A
KR20030020488A KR1020010052449A KR20010052449A KR20030020488A KR 20030020488 A KR20030020488 A KR 20030020488A KR 1020010052449 A KR1020010052449 A KR 1020010052449A KR 20010052449 A KR20010052449 A KR 20010052449A KR 20030020488 A KR20030020488 A KR 20030020488A
Authority
KR
South Korea
Prior art keywords
burn
extract
composition
bamboo
active ingredient
Prior art date
Application number
KR1020010052449A
Other languages
Korean (ko)
Inventor
강정훈
Original Assignee
강정훈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강정훈 filed Critical 강정훈
Priority to KR1020010052449A priority Critical patent/KR20030020488A/en
Publication of KR20030020488A publication Critical patent/KR20030020488A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/13Burn treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: Provided are a pharmaceutical composition for healing burn-injury which comprises a bamboo extract as active ingredient and a pharmaceutically acceptable carrier, thereby simplifying treatment procedure of burn-injury and treating it rapidly. CONSTITUTION: The pharmaceutical composition characteristically comprises a bamboo extract as active ingredient and is thus used for healing burn-injury. It further comprises an aloe extract or a cucumber extract, or their mixture. It further comprises antibiotics.

Description

대나무 추출물을 유효성분으로 하는 화상치료용 조성물{Pharmaceutical Composition for Healing Burn-injury Comprising Bamboo Extract as Active Ingredient}Pharmaceutical Composition for Healing Burn-injury Comprising Bamboo Extract as Active Ingredient}

본 발명은 대나무 추출물을 유효성분으로 하는 화상치료용 조성물에 관한 것이다. 좀 더 구체적으로, 본 발명은 대나무 추출물을 유효성분으로 함유하고, 약제학적으로 허용되는 담체를 포함하는 화상치료용 조성물에 관한 것이다.The present invention relates to a composition for burn treatment comprising the bamboo extract as an active ingredient. More specifically, the present invention relates to a composition for treating burns containing bamboo extract as an active ingredient and comprising a pharmaceutically acceptable carrier.

동물의 피부는 외부환경으로 부터 생체를 보호하는 1차적인 보호막으로서, 외부환경의 영향을 여과없이 받게 된다. 이러한 영향 중, 대기 오염물질 또는 자외선 등의 유해요인에 의한 손상이 두드러지는데, 자외선의 경우, 지구에 도달하는 빛의 0.5%에 해당하는 극히 적은 양이지만, 홍반, 색소침착, 주름 및 대부분의 피부암을 유발시키는 요소로서 작용한다고 알려져 있다. 최근에는 생태계의 불균형 및 불안정화로 인해서, 대기권의 오존층이 점차 얇아짐에 따라서 지표에 도달하는 자외선의 양은 점차 늘어가고 있으며, 오존층이 1% 감소함에 따라서 악성흑색종이 0.6%씩 증가한다고 보고되고 있는 실정이다.The skin of an animal is the primary protective film that protects the living body from the external environment, and receives the effects of the external environment without filtering. Among these effects, damage caused by harmful pollutants such as air pollutants or ultraviolet rays is prominent. In the case of ultraviolet rays, an extremely small amount corresponding to 0.5% of the light reaching the earth, erythema, pigmentation, wrinkles and most skin cancers It is known to act as an inducing factor. Recently, due to the imbalance and destabilization of the ecosystem, the amount of ultraviolet rays reaching the surface is gradually increasing as the ozone layer in the atmosphere becomes thinner, and malignant melanoma increases by 0.6% as the ozone layer decreases by 1%. to be.

일반적으로, 생물은 몸에 상처가 생길 경우, 그 상처 부위를 어느 정도 스스로 방어하고 자가치유를 하려고 하는 성질을 가지고 있다. 피부가 손상될 경우, 일정 수준의 이하의 피부손상은 자가치유 능력으로 회복될 수 있으나, 일정 수준 이상의 피부손상은 세균의 감염 등과 같은 기타 요인으로 인하여, 다른 질병으로 확산될 수도 있다. 특히, 자외선이나 가타 화기물질에 의한 화상으로 피부가 손상되는 경우, 피부조직의 손상 뿐만 아니라, 화독에 의한 추가적인 손상까지 발생하므로, 이를 조기에 치료하기 위하여, 화상치료용 상처치료 조성물을 사용한다. 전기 조성물은 생체 친화성이 우수하여 상처 부위에 있어서의 거부반응이 적고, 상처 부위와 밀착할 수 있어야 하며, 상처 부위의 세균 감염을 방지할 수 있어야 하고, 다른 의약품과 혼합하여 사용 하더라도 반응성이 없어야한다.In general, when a body is injured, the organism has the property of defending itself to some extent and self-healing. If the skin is damaged, the skin damage below a certain level can be recovered by the self-healing ability, but the skin damage above a certain level may spread to other diseases due to other factors such as bacterial infection. In particular, when the skin is damaged by a burn due to ultraviolet rays or other firearms, not only damage to the skin tissue, but also additional damage caused by poisoning, so as to treat this early, a wound treatment composition for burn treatment is used. The electrical composition should be excellent in biocompatibility, so it has little rejection at the wound site, can be in close contact with the wound site, can prevent bacterial infection at the wound site, and should not be reactive even when mixed with other medicines. do.

현재 화상이나 외상의 치료보조에 사용되고 있는 피부치료용 조성물은 손상을 입은 피부가 회복될 때까지 한시적으로 상처를 보호하고, 체내의 수분 누출을 방지하며, 삼출액-염증이 있을 때 병소(病巢)에 모인 액체를 흡수할 뿐만 아니라, 세균의 감염을 방지한다는 특징을 공유하고 있다. 이들을 종류별로 살펴보면, 피부흡수성이 우수한 겔을 주성분으로 하는 조성물, 폴리우레탄 막 또는 돼지 가죽의 동결건조물을 주성분으로 하는 조성물, 천연다당류인 키틴으로 피복된 다공질 막을 주성분으로 하는 조성물, 합성고분자 또는 함수성 젤라틴을 주성분으로 포함하는 조성물 등이 있다. 아울러, 이외의 물질을 사용한 상처치료 조성물이 개발되고 있으나, 이들은 합성된 물질을 주요성분으로 포함하고 있으며, 이들 물질들은 피부의 손상된 부위를 치료하는데 도움이 되지만, 정상조직에 대한 부작용이 조금씩 상존하고 있으므로, 이러한 문제점을 해결하기 위하여 천연물질을 주요성분으로 포함하는 상처치유 조성물을 개발하려는 노력이 계속되고 있다. 근래에 와서, 녹차추출물이 피부손상 및 피부질환의 치료에 효과적이라는 것이 밝혀져 있고, 이의 유효성분이 카테킨 화합물이라고 보고되어 있어, 이를 이용한 치료용 조성물의 개발이 연구되고 있다. 그러나, 대부분의 천연물로부터 제조되는 상처치유 조성물은 재료의 구입단가와 제조과정 중에 소요되는 비용이 막대하여 경제성이 없다는 단점을 극복하지 못하고 있는 실정이다.Skin treatment compositions currently used to aid in the treatment of burns or trauma protect the wound for a limited time until the damaged skin is restored, prevent the leakage of water in the body, and when the exudative fluid is inflamed. In addition to absorbing the collected liquid, it also shares the characteristics of preventing bacterial infection. Looking at them by type, a composition mainly composed of gel having excellent skin absorption property, a composition mainly composed of a polyurethane membrane or a freeze-dried product of pork skin, a composition mainly composed of a porous membrane coated with chitin, a natural polysaccharide, synthetic polymers or functionalities And a composition containing gelatin as a main component. In addition, wound healing compositions using other materials have been developed, but these include synthetic materials as the main ingredients, and these materials help to treat damaged areas of the skin, but side effects to normal tissues exist little by little. Therefore, in order to solve these problems, efforts have been made to develop wound healing compositions containing natural substances as main components. In recent years, it has been found that green tea extract is effective for the treatment of skin damage and skin diseases, and its active ingredient is reported to be a catechin compound, and development of a therapeutic composition using the same has been studied. However, the wound healing composition prepared from most natural products does not overcome the disadvantage that the cost of the material and the cost of the manufacturing process are enormous and economical.

또한, 전기 치료용 조성물을 이용하는 경우, 대체적으로 상처에 직접적으로 도포하여 사용하는데, 일반적인 창상에 비하여 화상은 긴 치료시간과 노력을 요구한다. 그 이유는 화독을 제거하는 과정, 화상에 따라 발생하는 수포를 제거하는 과정이 추가로 포함되기 때문인데, 이 때문에 일반 창상치료제와는 별도로 화상용 치료제가 개발되고 있는 실정이다. 그러나, 이처럼 개발된 치료제는 화독 및 수포를 제거한 후에 처리되는 것으로서, 1차적으로 제거된 화독에 의한 잔여손상을 방지하고 수포의 재발을 막을 수 있을 뿐, 1차적인 화독과 수포의 제거는 전통적인 방법에서 크게 발전하지 못하는 실정이다.In addition, in the case of using the composition for electrotherapy, it is generally applied directly to the wound, the burn requires a long treatment time and effort compared to the general wound. The reason for this is that the process of removing the poison and the process of removing the blisters caused by the burn are additionally included. Therefore, a treatment for burns is being developed separately from the general wound treatment. However, the therapeutic agent developed in this way is treated after removing the poison and blisters, which can prevent the residual damage caused by the first removed poison and prevent the reoccurrence of the blisters. The situation in the country does not develop much.

따라서, 효율적으로 화상을 치료할 수 있는 방법을 개발하여야 할 필요성이 끊임없이 대두되었다.Therefore, there is a constant need to develop a method for treating burns efficiently.

이에, 본 발명자들은 효율적으로 화상을 치료할 수 있는 방법을 개발하고자예의 연구노력한 결과, 대나무 추출물을 유효성분으로 하고, 약제학적으로 허용되는 담체를 포함하는 화상치료용 조성물을 이용할 경우, 별도의 화독 및 수포의 제거과정 없이, 신속하고 효과적으로 화상을 치료할 수 있음을 확인하고, 본 발명을 완성하게 되었다.Thus, the inventors of the present invention, as a result of research efforts to develop a method for treating burns efficiently, when using a composition for the treatment of burns comprising bamboo extract as an active ingredient, a pharmaceutically acceptable carrier, separate poisons and Without removing the blisters, it was confirmed that the burn can be treated quickly and effectively, and the present invention was completed.

결국, 본 발명의 주된 목적은 대나무 추출물을 유효성분으로 함유하는 화상치료용 조성물을 제공하는 것이다.After all, the main object of the present invention is to provide a composition for burn treatment containing bamboo extract as an active ingredient.

본 발명의 화상치료용 조성물은 대나무 추출물을 유효성분으로 함유하고, 약제학적으로 허용되는 담체를 포함한다: 이때, 알로에 추출물 및 오이 추출물을 추가로 포함할 수도 있으며, 대나무 추출물, 오이 추출물 및 알로에 추출물은 90:5:5 내지 70:15:15(w/w/w)로 혼합함이 바람직하다.The composition for treating burns of the present invention contains a bamboo extract as an active ingredient, and includes a pharmaceutically acceptable carrier: at this time, it may further include aloe extract and cucumber extract, bamboo extract, cucumber extract and aloe extract Silver is preferably mixed at 90: 5: 5 to 70:15:15 (w / w / w).

대나무는 그의 생태적인 특성으로 인하여 극동아시아 지역에서 선호되어 온 식물이다. 특히, 대나무는 그의 형태적인 특성뿐만 아니라, 그의 기능성으로 인하여 예로부터 크게 사랑 받아 왔다. 예를 들어, 본초강목(本草綱目)에는 대나무를 활용한 처방 34종류가 기록되어 있고, 신농본초경(神農本草經) 및 동의보감(東醫寶鑑)에는 해소와 상기 종양, 해열, 살충, 구토, 곽난, 거담, 중풍, 당뇨병, 고혈압, 신경쇠약, 임신빈혈, 소아 전염질환, 간질, 불면증, 음주과다, 피로회복, 안구통증 등에 효과가 있다고 기술되어 있으며, 특히, 동의보감(東醫寶鑑) 하편(下篇) 목부본초(木部本草)에는 '죽여(竹茹)는 담죽의 얇은 속껍질을 깎아서 솜처럼 한 것으로 진정, 해열, 지혈의 효과가 있고, 죽력(竹瀝)은 대에서 나온 기름으로 폭중풍(暴中風), 졸중풍(卒中風), 파상풍(破傷風)및 산후발열에 효과가 있으며, 죽황(粥黃)은 대나무 마디 속의 황백(黃白)한 막으로서 맛이 달고 단석(丹石)의 약독(藥毒)과 열이 나는 것을 제압해 준다'고 기록되어 있을 뿐만 아니라, 대나무를 태워만든 대나무 숯이나 대나무에 천일염을 담아 구워낸 죽염의 효능 등 대나무의 약리작용은 무수하다. 그러나, 이러한 대나무의 약리효과는 대부분 대나무 추출물을 경구투여 방법으로 투여한 후, 검증된 효과로서, 대나무 추출물의 외용효과에 대하여는 특별히 밝혀지지 않았다.Bamboo is a preferred plant in Far East Asia because of its ecological characteristics. In particular, bamboo has been greatly loved since ancient times because of its functionality as well as its form. For example, 34 kinds of prescriptions using bamboo have been recorded in the herbaceous cortex, and in the New Nongbyeon Herbal Cultivation and Dongbobogam, the remedy and the tumor, fever, insecticide, vomiting, It is said to be effective in swelling, expectoration, stroke, diabetes, high blood pressure, nervous breakdown, pregnancy anemia, pediatric infectious diseases, epilepsy, insomnia, excessive drinking, fatigue, and eye pain. (下 죽) In Mokbu-chocho, `` Kimchi '' is made by cutting the thin skin of ivy, and has the effect of calming, fever, and hemostasis. It is effective in heavy winds, strokes, tetanus and postpartum fever. Bamboo bamboo is a yellow-white film in bamboo nodes, sweet and tasteless. To overpower the aggression and fever of God. ' The pharmacological effects of bamboo are numerous, such as bamboo charcoal made of bamboo, and bamboo salt baked with sun salt in bamboo. However, the pharmacological effect of the bamboo is a proven effect after most of the bamboo extract orally administered method, the external effect of the bamboo extract was not particularly revealed.

본 발명자는 대나무 추출물의 외용효과를 연구한 결과, 대나무 추출물이 화독 및 수포를 제거하는데 우수함을 확인할 수 있었다. 특히, 수포제거 방법에 있어서, 종래에는 수포에 포함된 수분을 제거하더라도, 수포의 표피가 상처부위에 밀착되지 않아 원활한 치료를 방해하므로, 전기 표피를 제거하지만, 대나무 추출물을 수분이 제거되지 않은 수포의 표면에 도포하면, 수포에 함유된 수분이 소실되고, 수포의 표피가 화상부위에 다시 밀착되며, 화상으로 손상된 피부조직이 신속하게 회복됨을 알게 되었다. 또한, 종래의 방법으로는 수포의 표피가 제거된 부위에 외부 병원균의 감염을 방지하기 위하여 별도의 소독 및 항생물질을 처리하여야 하지만, 본 발명의 화상치료용 조성물을 이용하느 경우에는 수포의 표피가 손실되지 않으므로, 별도의 소독 및 항생물질을 처리하는 단계를 생략하거나 간소화시킬 수 있다.The present inventors studied the external effects of the bamboo extract, it was confirmed that the bamboo extract is excellent in removing poison and blisters. In particular, in the method of removing blisters, even if the moisture contained in the blisters is conventionally removed, the epidermis of the blisters does not adhere to the wound site and thus prevents the smooth treatment. When applied to the surface of, the moisture contained in the blisters was lost, the epidermis of the blisters were brought into close contact with the burned area, and the skin tissue damaged by the burns was quickly recovered. In addition, the conventional method has to be treated with a separate disinfection and antibiotics to prevent infection of external pathogens in the area where the epidermis of the blister is removed, but when using the burn treatment composition of the present invention Since it is not lost, separate disinfection and treatment of antibiotics can be omitted or simplified.

본 발명의 화상치료용 조성물의 유효성분으로 함유되는 대나무 추출물은 약학적으로 허용가능한 결합제(예, 폴리비닐피롤리돈, 하이드록시프로필셀룰로오스), 붕해제(예, 카복시메틸셀룰로오스칼슘, 전분글리콜산나트륨), 희석제(예, 옥수수전분, 유당, 콩기름, 결정셀룰로오스, 만니톨), 활택제(예, 스테아린산 마그네슘, 탈크), 안정제(카복시메틸셀룰로오스나트륨, 알파 또는 베타 싸이클로 덱스트린, 비타민 C, 구연산, 백납), 보존료(예, 파라옥시안식향산메틸, 파라옥시안식향산프로필, 안식향산나트륨) 또는 향료(예, 에틸바닐린, 마스킹후레바, 멘톨후라보노, 허브향)와 혼합하여, 정제, 다공성 막, 분말제, 겔제, 연고제, 크림제, 액제 등의 약학적 제제로 제조될 수 있다. 또한, 외부 감염균에 의한 추가적인 진피감염을 막기 위하여, 상용량의 공지된 항생물질을 추가로 포함할 수도 있다.Bamboo extract contained as an active ingredient of the burn treatment composition of the present invention is a pharmaceutically acceptable binder (eg, polyvinylpyrrolidone, hydroxypropyl cellulose), disintegrant (eg, carboxymethyl cellulose calcium, starch glycolic acid Sodium), diluents (e.g. corn starch, lactose, soybean oil, crystalline cellulose, mannitol), lubricants (e.g. magnesium stearate, talc), stabilizers (sodium carboxymethylcellulose, alpha or beta cyclodextrin, vitamin C, citric acid, white lead) ), Preservatives (e.g. methyl paraoxybenzoate, propyl paraoxybenzoate, sodium benzoate) or flavorings (e.g. ethyl vanillin, masking flavors, menthol flavono, herbal flavors), tablets, porous membranes, powders, It may be prepared as a pharmaceutical preparation such as gels, ointments, creams, solutions. In addition, in order to prevent further dermal infection by external infectious bacteria, it may further comprise a normal dose of known antibiotics.

투여량Dosage

화상치료용 조성물의 투여량은 환자의 연령, 체중 및 창상의 정도에 따라 차이가 있으나, 통상 성인(체중 60kg 기준)의 경우 비경구로 1일 1 내지 5회 0.01 내지 0.06g/cm2의 양으로 화상부위에 도포하는 것이 바람직하며, 본 발명의 분야에서 통상의 지식을 가진 자의 경험에 의하여 적절히 결정될 수도 있다.The dosage of the composition for the treatment of burns varies depending on the age, weight, and the degree of wound of the patient, but in the case of adults (based on 60 kg body weight), usually in an amount of 0.01 to 0.06 g / cm 2 1-5 times a day parenterally. It is preferable to apply to the burned area, and may be appropriately determined by the experience of those skilled in the art.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. .

실시예 1: 화상치료용 조성물의 제조 Example 1 Preparation of Burn Treatment Composition

20cm의 크기로 절단된 4년생 대나무 10kg을 증기를 수집할 수 있도록 고안된 압력솥에 넣고, 밀폐시킨 후, 120℃로 24시간 동안 가열하며, 발생된 증기를 수집하여, 냉각시켜서, 대나무 추출물 1kg을 수득하였다. 전기 수득한 대나무 추출물 800g, 오이즙 100g 및 알로에즙 100g을 교반하며 혼합하고, 50℃에서 5시간 동안 건조시켜서, 오일상의 화상치료용 조성물을 제조하였다.10 kg of 4 year-old bamboo cut to a size of 20 cm is placed in a pressure cooker designed to collect steam, sealed, heated to 120 ° C. for 24 hours, and the generated steam is collected and cooled to obtain 1 kg of bamboo extract. It was. 800 g of the obtained bamboo extract, 100 g of cucumber juice and 100 g of aloe juice were mixed with stirring, and dried at 50 ° C. for 5 hours to prepare an oily burn composition.

실시예 2: 화상치료용 조성물의 화상치료 효과 Example 2 Burn Treatment Effect of Burn Composition

본 발명의 화상치료용 조성물의 화상치료 효과를 여러종류의 화상치료방법에 의한 화상치료 효과와 비교하였다.The burn treatment effect of the burn treatment composition of the present invention was compared with the burn treatment effect by various burn treatment methods.

실시예 2-1: 화상치료용 조성물의 효과(Ⅰ) Example 2-1 : Effect of the composition for burn treatment (I)

8주령(체중 2Kg)의 건강한 웅성 가토(New Zealand White Rabbit, 대한 동물사육 센터)를 사육실 조건에서 사료(제일유지 사료)와 물(drinking water)은 무제한 공급하며 사육하였다. 이어, 실험동물 피부 중, 견갑하각(inferior border of scapular)에서 수평으로 5cm 이동한 부위에 위치한 2 ×2cm 넓이의 피부를 화상처리부위로 지정하고, 지정된 부위를 소독한 다음, 고온으로 처리된 2 ×2cm 넓이의 금속판으로 화상을 입혔다. 2시간 경과 후, 전기 제조된 상처치료 조성물을 5일 동안 8시간 간격으로 화상부위에 0.025g/cm2양으로 도포한 실험군과 포타딘을 이용하여 소독치료만을 수행한 대조군을 제작하고, 대조군과 심험군에 있어서, 초기 화상면적에 대하여, 경과 일수에 따른 화상면적의 비율을 구하여 화상잔존율(%)을 측정하였다(참조: 표 1)A healthy male New Zealand white rabbit (8 kg body weight) of 8 weeks old (weight 2 kg) was bred under unlimited conditions of feeding (drinking feed) and drinking water. Subsequently, 2 × 2cm wide skin located 5% horizontally from the inferior border of scapular of the experimental animal skin was designated as an image processing site, and the designated area was disinfected, The plate was burned with a metal plate having a width of 2 cm. After 2 hours, the experimental group was applied to the burn site at an interval of 0.025 g / cm 2 in the burned area for 8 days for 5 days, and a control group was treated with only disinfection using potadidine. In the cardiac group, the percentage of image area with respect to the number of days was determined with respect to the initial image area, and the image survival rate (%) was measured (see Table 1).

시간의 경과에 따른 화상잔존율(%)의 변화Change in Image Retention Rate (%) Over Time 경과일수Elapsed days 대조군Control 실험군Experimental group 1One 95.3 ±0.695.3 ± 0.6 80.1 ±0.880.1 ± 0.8 22 86.4 ±0.486.4 ± 0.4 55.3 ±0.455.3 ± 0.4 33 79.8 ±0.779.8 ± 0.7 32.1 ±0.332.1 ± 0.3 44 71.2 ±0.371.2 ± 0.3 10.6 ±0.410.6 ± 0.4 55 60.8 ±1.260.8 ± 1.2 2.8 ±0.62.8 ± 0.6

상기 표 1에서 보듯이, 실험군의 화상잔존율이 신속하게 감소함을 알 수 있었고, 대조군에서는 약 3.5일 동안 수포가 잔존하였으나, 실험군에서는 수포의 잔존시간이 20시간에 불과하였으므로, 수포의 제거면에서 본 발명의 화상치료용 조성물이 우수함을 알 수 있었다.As shown in Table 1, it was found that the burn residual rate of the experimental group was rapidly decreased, and the blister remained for about 3.5 days in the control group, but in the experimental group, the blister remaining time was only 20 hours, so that the blisters were removed. It was found that the composition for burn treatment of the present invention is excellent.

실시예 2-2: 화상치료용 조성물의 효과(Ⅱ) Example 2-2 : Effect of the composition for burn treatment (II)

대조군을 시중에서 구입한 화상치료제(바셀린)을 화상부위에 도포하는 것을 제외하고는, 실시예 2-1과 동일한 방법으로 화상잔존율(%)을 측정하였다(참조: 표 2)Residual burn rate (%) was measured in the same manner as in Example 2-1, except that a commercially available burn treatment agent (petrolatum) was applied to the burn site (see Table 2).

시간의 경과에 따른 화상잔존율(%)의 변화Change in Image Retention Rate (%) Over Time 경과일수Elapsed days 대조군Control 실험군Experimental group 1One 90.3 ±0.290.3 ± 0.2 80.1 ±0.880.1 ± 0.8 22 76.4 ±0.976.4 ± 0.9 55.3 ±0.455.3 ± 0.4 33 59.8 ±0.659.8 ± 0.6 32.1 ±0.332.1 ± 0.3 44 31.2 ±0.731.2 ± 0.7 10.6 ±0.410.6 ± 0.4 55 20.8 ±0.220.8 ± 0.2 2.8 ±0.62.8 ± 0.6

상기 표 2에서 보듯이, 시중에서 시판되는 화상치료제를 사용한 대조군 보다, 본 발명의 화상치료용 조성물을 이용한 실험군의 화상잔존율이 신속하게 감소함을 알 수 있었고, 대조군에서는 약 1.5일 동안 수포가 잔존하였으나, 실험군에서는 수포의 잔존시간이 20시간에 불과하였으므로, 수포의 제거면에서 본 발명의 화상치료용 조성물이 우수함을 알 수 있었다.As shown in Table 2, it was found that the burn residual rate of the experimental group using the burn treatment composition of the present invention was reduced more rapidly than the control using a commercially available burn treatment agent, and the blisters in the control group were about 1.5 days. Although remaining in the experimental group, the remaining time of the blister was only 20 hours, it was found that the composition for burn treatment of the present invention is excellent in terms of removing the blister.

실시예 2-3: 화상치료용 조성물의 효과(Ⅲ) Example 2-3 : Effect of Burn Treatment Composition (III)

대조군의 수포를 인위적으로 제거하고, 화상부위를 소독한 다음, 시중에서 구입한 화상치료제(바셀린)을 화상부위에 도포하는 것을 제외하고는, 실시예 2-1과 동일한 방법으로 화상잔존율(%)을 측정하였다(참조: 표 3)Remaining burn rate (%) in the same manner as in Example 2-1, except that the blisters of the control group were artificially removed, the burned area was disinfected, and then a commercially available burn treatment agent (petrolatum) was applied to the burned area. ) Was measured (see Table 3).

시간의 경과에 따른 화상잔존율(%)의 변화Change in Image Retention Rate (%) Over Time 경과일수Elapsed days 대조군Control 실험군Experimental group 1One 85.3 ±0.285.3 ± 0.2 80.1 ±0.880.1 ± 0.8 22 66.4 ±0.966.4 ± 0.9 55.3 ±0.455.3 ± 0.4 33 42.8 ±0.642.8 ± 0.6 32.1 ±0.332.1 ± 0.3 44 19.2 ±0.719.2 ± 0.7 10.6 ±0.410.6 ± 0.4 55 8.8 ±0.28.8 ± 0.2 2.8 ±0.62.8 ± 0.6

상기 표 3에서 보듯이, 수포를 제거하고 시중에서 시판되는 화상치료제를 사용한 대조군 보다, 본 발명의 화상치료용 조성물을 이용한 실험군의 화상잔존율이 신속하게 감소함을 알 수 있었고, 비록 인위적인 수포의 제거로 인하여 수포는 없지만, 제거된 부위로 외부 감염균의 감염으로 인한 질병의 발생을 억제하기 위하여, 추가적인 항생울질을 처리하여야 하므로, 화상치료용 조성물만을 처리하는 실험군이 보다 우수함을 알 수 있었다.As shown in Table 3, it was found that the burn residual rate of the experimental group using the burn treatment composition of the present invention was reduced more rapidly than the control group using the commercially available burn treatment agent by removing the blisters. There is no blister due to the removal, but in order to suppress the occurrence of the disease caused by the infection of the external infectious bacteria to the removed site, additional antibiotics were to be treated, it was found that the experimental group treated with only the burn treatment composition is better.

실시예 3: 상처치료 조성물의 피부 독성 평가 Example 3 Evaluation of Skin Toxicity of Wound Care Compositions

본 발명의 상처치유 조성물의 피부 부작용을 살펴보기 위하여 웅성가토를 대상으로 하여 폐쇄첩포 방법을 이용한 피부 독성 평가를 실시 하였다.In order to examine the side effects of the wound healing composition of the present invention, male rabbits were subjected to skin toxicity evaluation using a closed patch method.

8주령(체중 2kg)의 건강한 웅성 가토(New Zealand White Rabbit, 대한 동물 사육 센터)를 사육실 조건에서 사육하고, 실험동물의 등쪽 피부를 동물용 치퍼(clipper)를 사용하여 제모한 후, 실시예 1에서 제조한 화상치료용 조성물을 5g/cm2의 양으로 첩포용지(3M paper)에 도포한 다음, 제모 부위에 첩포하고 첩포가 떨어지지 않도록 압박붕대로 웅성 가토의 등배부위를 감싸 주었다. 이어, 48시간이 경과한 후, 첩포를 제거하고 첩포 부위를 육안 관찰한 결과, 어떠한 실험동물의 제모부위에서도 홍반이나 부종 등의 부작용이 발생하지 않음을 알게되어, 본 발명의 상처치료 조성물이 충분히 안전함을 알 수 있었다.8 weeks old (2 kg body weight) healthy male rabbit (New Zealand White Rabbit, Animal Breeding Center) was bred under the conditions of the breeding room, and the back skin of the experimental animal was depilated using an animal chipper, Example 1 The burn treatment composition prepared in the above was applied to the patch paper (3M paper) in the amount of 5g / cm 2 , and then patched on the hair removal site and wrapped in the back of the male rabbit with a pressure bandage so that the patch does not fall. Subsequently, after 48 hours, the patch was removed and the patch was visually observed. As a result, it was found that no side effects such as erythema or edema occurred in the hair removal site of any experimental animal. It was safe.

이상에서 상세히 설명하고 입증하였듯이, 본 발명은 대나무 추출물을 유효성분으로 함유하고, 약제학적으로 허용되는 담체를 포함하는 화상치료용 조성물을 제공한다. 본 발명의 화상치료용 조성물은 대나무 추출물을 유효성분으로 함유하고, 약제학적으로 허용되는 담체를 포함한다. 본 발명의 화상치료용 조성물을 이용할 경우, 화독 및 수포를 제거하는 단계를 생략하거나 간소화 할 수 있으므로, 화상의 신속하고 간편한 치료에 널리 이용될 수 있을 것이다.As described and demonstrated in detail above, the present invention provides a composition for the treatment of burns containing bamboo extract as an active ingredient and a pharmaceutically acceptable carrier. The burn treatment composition of the present invention contains a bamboo extract as an active ingredient, and includes a pharmaceutically acceptable carrier. When using the composition for the treatment of burns of the present invention, it is possible to omit or simplify the step of removing poisonous and blisters, and thus it may be widely used for quick and easy treatment of burns.

Claims (6)

대나무 추출물을 유효성분으로 포함하고, 약제학적으로 허용가능한 담체를 포함하는 화상치료용 조성물.Burn composition comprising a bamboo extract as an active ingredient, comprising a pharmaceutically acceptable carrier. 제 1항에 있어서,The method of claim 1, 알로에 추출물, 오이 추출물 또는 전기 추출물의 혼합물을 추가로Adding a mixture of aloe extract, cucumber extract or electric extract 포함하는 것을 특징으로 하는Characterized in that it comprises 화상치료용 조성물.Burn treatment composition. 제 2항에 있어서,The method of claim 2, 대나무 추출물, 오이 추출물 및 알로에 추출물의 혼합비는 90:5:5The mixing ratio of bamboo extract, cucumber extract and aloe extract is 90: 5: 5 내지 70:15:15(w/w/w)인 것을 특징으로 하는To 70:15:15 (w / w / w) 화상치료용 조성물.Burn treatment composition. 제 1항에 있어서,The method of claim 1, 상용량의 공지된 항생물질을 추가로 포함하는 것을 특징으로 하는Characterized in that it further comprises a normal dose of known antibiotics. 화상치료용 조성물.Burn treatment composition. 제 1항에 있어서,The method of claim 1, 약제학적으로 허용가능한 담체는 결합제, 붕해제, 희석제, 활택제,Pharmaceutically acceptable carriers include binders, disintegrants, diluents, glidants, 안정제, 보존료 또는 향료인 것을 특징으로 하는Stabilizer, preservative or flavoring 화상치료용 조성물.Burn treatment composition. 제 1항에 있어서,The method of claim 1, 정제, 다공성 막, 분말제, 겔제, 연고제, 크림제 또는 액제의Of tablets, porous membranes, powders, gels, ointments, creams or solutions 제형인 것을 특징으로 하는Characterized in that the formulation 화상치료용 조성물.Burn treatment composition.
KR1020010052449A 2001-08-29 2001-08-29 Pharmaceutical composition for healing burn-injury comprising bamboo extract as active ingredient KR20030020488A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020010052449A KR20030020488A (en) 2001-08-29 2001-08-29 Pharmaceutical composition for healing burn-injury comprising bamboo extract as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020010052449A KR20030020488A (en) 2001-08-29 2001-08-29 Pharmaceutical composition for healing burn-injury comprising bamboo extract as active ingredient

Publications (1)

Publication Number Publication Date
KR20030020488A true KR20030020488A (en) 2003-03-10

Family

ID=27721373

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020010052449A KR20030020488A (en) 2001-08-29 2001-08-29 Pharmaceutical composition for healing burn-injury comprising bamboo extract as active ingredient

Country Status (1)

Country Link
KR (1) KR20030020488A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095352A1 (en) 2015-12-01 2017-06-08 Ataturk Universitesi Bilimsel Arastirma Projeleri Birimi Use of wax, olive oil, butter mixture and/ or its combination with varying ratios of boron and/ or derivatives thereof, in treatment of wounds, burns, and skin diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0156623B1 (en) * 1994-12-27 1998-11-16 이연호 Remedy composition for epithelial cell
KR101138471B1 (en) * 2003-07-25 2012-04-25 화이자 인코포레이티드 Tricyclic parp inhibitors
KR101183967B1 (en) * 2010-02-16 2012-09-18 조선대학교산학협력단 Functionally graded Transparent conducting oxide film and method for manufacturing thereof, Anode for Organic light emitting diode and window layer for solar cell using functionally graded transparent conducting oxide film
KR101297748B1 (en) * 2011-10-11 2013-08-20 익스팬테크주식회사 Feed-through type filter for shielding and surge protecting
KR101298723B1 (en) * 2011-06-28 2013-08-21 현대제철 주식회사 Apparatus for treating exhaust gas and method for treating exhaust gas with the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0156623B1 (en) * 1994-12-27 1998-11-16 이연호 Remedy composition for epithelial cell
KR101138471B1 (en) * 2003-07-25 2012-04-25 화이자 인코포레이티드 Tricyclic parp inhibitors
KR101183967B1 (en) * 2010-02-16 2012-09-18 조선대학교산학협력단 Functionally graded Transparent conducting oxide film and method for manufacturing thereof, Anode for Organic light emitting diode and window layer for solar cell using functionally graded transparent conducting oxide film
KR101298723B1 (en) * 2011-06-28 2013-08-21 현대제철 주식회사 Apparatus for treating exhaust gas and method for treating exhaust gas with the same
KR101297748B1 (en) * 2011-10-11 2013-08-20 익스팬테크주식회사 Feed-through type filter for shielding and surge protecting

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095352A1 (en) 2015-12-01 2017-06-08 Ataturk Universitesi Bilimsel Arastirma Projeleri Birimi Use of wax, olive oil, butter mixture and/ or its combination with varying ratios of boron and/ or derivatives thereof, in treatment of wounds, burns, and skin diseases

Similar Documents

Publication Publication Date Title
JP6778219B2 (en) Igai adhesive protein products that suppress skin inflammation and their applications
US8426384B2 (en) Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate
CN102327419A (en) External use medicine for treating wound healing
Doanh et al. The use of a water extract from the bark of Choerospondias axillaris in the treatment of second decree burns
WO2017030388A1 (en) Composition for treating skin wounds
KR20010109042A (en) A cataplasma containing an aloe concentrate which shows an anti-inflammatory effect
KR20030020488A (en) Pharmaceutical composition for healing burn-injury comprising bamboo extract as active ingredient
KR20100088478A (en) Composition for treatment of a burn and preparing method thereof
KR20040009342A (en) Drug for treatment of a burn and preparing process thereof
WO2007144723A2 (en) Use of plants of carpobrotus edulis as anti-itching and/or anti-inflammatory agents
KR101607229B1 (en) A composition for treating wound containing horse oil
KR101081134B1 (en) A method of preparing a pharmaceutical formulation for treating burn
KR20120090123A (en) Composition of film forming solution for alleviation of menstrual cramp
RU2355411C1 (en) Wound- healing ointment
CN101590125B (en) Medicament for treating empyrosis and using method thereof
KR20100111061A (en) Composition for wound healing
KR100289906B1 (en) Dermatological composition
Chaurasiya et al. OFLOXACIN POLYHERBAL TOPICAL GEL
KR20220144070A (en) Burn treatment composition containing egg shell powder as an active ingredient
Waqiah et al. Potential Of Moringa Leaf Extract (Moringa Oleifera Lam) As Wound Medicine In Livestock
CN110433236A (en) A kind of Chinese medicine composition and its preparation method and application promoting wound healing
KR20020087210A (en) Composition for Healing Injury
RU2124355C1 (en) Method of an agent devising for wound treatment
RU2122859C1 (en) Phytoconcentrate with curative-prophylactic effect used in gastroenterology
KR101081106B1 (en) A pharmaceutical formulation comprising the extract of mixed herbs useful in treating burn and the method for preparing thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application